(CercleFinance.com) – Merck announced on Tuesday that the US Food and Drug Administration (FDA) has approved Prevymis as a prophylactic treatment for cytomegalovirus in kidney transplant recipients at high risk of contracting the infection.
This decision, which comes in the wake of a priority review, follows the green light, in 2017, of the drug for the prophylaxis of a cytomegalovirus (CMV) infection in adults seropositive for CMV who have received a transplant of allogeneic hematopoietic stem cells (HSCG) [R+].
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
